The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government.
Know the risks and potential benefits of clinical studies and talk to your health care provider before participating.
Read our disclaimer for details.
The purpose of this study is to define the natural history of Mucolipidosis Type IV and identify potential clinical outcome measures.
Condition or disease
Mucolipidosis Type IV
Mucolipidosis type IV (MLIV) is an autosomal recessive disorder typically characterized by severe psychomotor delay evident by the end of the first year of life and slowly progressive visual impairment during the first decade as a result of a combination of corneal clouding and retinal degeneration. By the end of the first decade of life, and always by their early teens, individuals with typical MLIV develop severe visual impairment as a result of retinal degeneration. MLIV is an under-diagnosed and unique lysosomal disorder in that it often is mistaken either for cerebral palsy or for a retinal dystrophy of unknown cause. In addition, it is caused by a defect in a cation channel rather than by a lysosomal hydrolase. This study represents the only prospective clinical study in this patient population. Now that an animal model has been created and novel therapies will likely be tested, it is particularly important to define the natural history of this disorder and identify potential clinical outcome measures.
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Layout table for eligibility information
Ages Eligible for Study:
1 Year to 64 Years (Child, Adult)
Sexes Eligible for Study:
Accepts Healthy Volunteers:
Subjects previously identified with Mucolipidosis Type IV
Have a definitive diagnosis of MLIV based at least on a compatible history and significantly elevated blood gastrin levels
Be able to travel to the Baylor Institute of Metabolic Disease in Dallas and spend 2-3 working days on site
Be able to tolerate a general exam and neurological exam
Be able to tolerate a modest amount of blood drawing, provide a urine specimen, and have a skin biopsy(if not previously done)
Be able to tolerate the performance of necessary neuroimaging studies to include EEG and Head MRI
Be able to tolerate a neuropsychological testing and rehabilitation evaluation